Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Jul 10;15:4899–4918. doi: 10.2147/IJN.S244712

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2020 Tsolou et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

Monitoring of Paclitaxel-loaded PPSu-PEG NPs cell toxicity versus free Paclitaxel. HeLa K and MCF7 cells were treated with either Paclitaxel-loaded PPSu-PEG NPs, or free Paclitaxel and real-time monitored for 48 h after drug addition, using the RTCA assay. (A) Graphs representing normalized cell index of HeLa K cells treated with (i) Paclitaxel-loaded PPSu-PEG NPs (ii) free Paclitaxel, (B) Graphs representing normalized cell index of MCF7 cells treated with (i) Paclitaxel-loaded PPSu-PEG NPs, and (ii) free Paclitaxel. Cells were treated in duplicates with the indicated concentrations. (C–D) Dose response curves resulting from the RTCA assay for IC₅₀ values of HeLa K (C) and MCF7 cells (D), treated with either Paclitaxel-loaded PPSu-PEG NPs (NPs-Paclitaxel) or free Paclitaxel.